The FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market immediately, after a review failed to alleviate concerns about a cancer risk.

NDMA is a probable human carcinogen, a substance that could cause cancer, the FDA said in April 2020, when the agency asked ...

This lawsuit concerns GSK’s fraud on the federal and state governments and the money spent on ranitidine products by governments because of that fraud. Whether ranitidine increases the risk of cancer ...

In a statement Wednesday, Valisure said the results from its research on acne treatments were most similar to its ...

GSK and Sanofi have both said that NDMA levels in ranitidine products is lower than would be encountered naturally in the diet. In its latest statement, GSK notes that a multidistrict litigation ...

UK doctors are being told to stop prescribing four types of a heartburn medication called Zantac or ranitidine as a "precautionary measure". It follows concern in several countries that products ...

US retailer CVS has become the latest to suspend the sale of a heartburn drug being investigated for links to cancer. It follows concern in several countries over the presence of impurities in ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

This came after studies revealed that ranitidine products might have unhealthy levels of NDMA, a known probable carcinogen that can lead to the development of cancer in users. While former Zantac ...

Only two commercial ranitidine products were assessed for NDMA content via analysis. Powdered samples (100 to 500 mg) were introduced to 10 mL headspace vials for headspace analysis without ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.

GSK has also reached an agreement to pay $70 million to resolve the Zantac Qui Tam suit previously filed by Valisure. The arrangement is awaiting final approval from the Department of Justice.